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Introduction
Thrombotic microangiopathy (TMA) describes a patho-
logical process of microvascular thrombosis, consumptive
thrombocytopenia and microangiopathic haemolytic
anaemia, leading to end-organ ischaemia and infarction.
TMA is a feature of a number of clinical disorders, most
commonly hemolytic uremic syndrome (HUS) and
thrombotic thrombocytopaenic purpura. Several molecu-
lar mechanisms mediating TMA have been elucidated;
however, challenges remain in distinguishing specific
causes of TMA in the presence of overlapping clinical
features.
Objectives
We aim to report a case of thrombotic microangiopathy,
rapidly progressive glomerulonephritis and amebic
colitis.
Methods
A 12 year old previously healthy boy was admitted with
acute renal injury, requiring dialysis. Initial lab exams
revealed urea of 213 mg/dL, creatinine 6.0 mg/dL, hema-
tocrit 18%, hemoglobin 7 g/dL, thrombocytopenia, LDH
5900 mg/dL, urine protein-to-creatinine ratio of 4.3, and
low C3. Due to evolution with myocardial dysfunction and
pericardial tamponade, IV methylprednisolone (MP)
pulses were started and he developed massive gastrointest-
inal bleeding due to amebic colitis, evidenced at colonic
biopsy. Plasmapheresis, gammaglobulin, metronidazole
and teclosan, were initiated, and after infection control:
MP pulses, Rituximab, cyclophosphamide and therapeutic
low-molecular weight heparin. Renal biopsy revealed cres-
centic glomerulonephritis, IgG and C3 on glomeruli, and
C1q tubular deposits, but also arteriolar TMA. Despite
this, he developed end stage renal disease. Serial autoanti-
bodies tests were negative. ADAMTS13 activity assay was
80%. Immunological investigation performed after immu-
nosuppression showed persistent and marked reduction of
serum IgA/IgM/IgG and lymphocyte, even after disconti-
nuation of cyclophosphamide and rituximab. This patient
currently has mild thrombocytopenia, leukopenia, lympho-
penia, laboratorial signs of hemolysis, and livedo reticu-
laris. Genetic studies for complement-mediated diseases
are pending.
Results
This is a case with severe evolution, characterized by
rapidly progressive glomerulonephritis and TMA. The
main question is whether this patient has atypical HUS,
perhaps associated with amebic dysentery, or an antipho-
spholipid syndrome. The persistently negative autoantibo-
dies, and the partial response to the adopted treatment,
made pSLE less probable.
Conclusion
The persistent active disease and the extreme difficulty of
vascular access for renal replacement therapy make it
urgent to perform kidney transplantation. Considering the
high risk of disease relapse and subsequent loss of renal
graft, it is essential to confirm the diagnosis to decide to
use eculizumab (anti-C5 monoclonal antibody) or not, and
especially to ensure better post-transplant prognosis.
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